Clidinium

CHEMBL620 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

352.4 g/mol

LogP

3.3

Phase

4

An anticholinergic agent that reduces stomach acid secretion and relieves gastrointestinal muscle spasms by blocking muscarinic receptors. It is often combined with a benzodiazepine to treat irritable bowel syndrome and peptic ulcers.

आणविक भार

352.4000 g/mol

LogP

3.30

TPSA

46.50 Å²

लिपिंस्की RO5

उत्तीर्ण

क्रिया का तंत्र

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2

InChI

InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1

Molecular Formula

C22H26NO3+

HBD / HBA

1 / 3

घूर्णनीय बंधन

5

भारी परमाणु

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An anticholinergic agent that reduces stomach acid secretion and relieves gastrointestinal muscle spasms by blocking muscarinic receptors. It is often combined with a benzodiazepine to treat irritable bowel syndrome and peptic ulcers.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Clidinium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL620. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2784. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Clidinium PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C22H26NO3+
पर्यायवाची: 4

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.